Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "IMA"

3519 News Found

4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy
Drug Approval | January 12, 2026

4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy

Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function


MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
Clinical Trials | January 12, 2026

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms


FDA rejects Vanda’s jet lag drug in current form
Drug Approval | January 12, 2026

FDA rejects Vanda’s jet lag drug in current form

Vanda strongly disputes the FDA’s reasoning


AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility
News | January 12, 2026

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility

Supports production of AbbVie's current and next-generation immunology and neuroscience medicines


Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
News | January 11, 2026

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients


Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy
News | January 11, 2026

Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab


NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
Clinical Trials | January 11, 2026

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial

The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases


InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
Biopharma | January 11, 2026

InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development


Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
Clinical Trials | January 11, 2026

Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC

KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer